


That which is claimed is:

1. Use of a compound of the formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a hedgehog pathway-dependent cancer in a subject.

2. The use according to claim 1, wherein the cancer is basal cell carcinoma (BCC).
3. The use of claim 1 or 2, wherein the cancer comprises a constitutively active hedgehog pathway.
4. The use of any one of claims 1 to 3, wherein the cancer is metastatic.
5. The use of any one of claims 1 to 4, wherein multiple cycles of treatment are to be administered to the subject for a time period sufficient to effect at least a partial tumor response.
6. The use of claim 5, wherein the time period is at least 6 months.
7. The use of claim 6, wherein the time period is at least 12 months.
8. The use of any one of claims 5 to 7, wherein multiple cycles of treatment are to be administered to the subject for a time period sufficient to effect a complete tumor response.
9. The use of any one of claims 5 to 8, wherein the medicament is to be administered to the subject according to a daily dosing regimen or intermittently.
10. The use of any one of claims 1 to 9, wherein an additional anti-cancer therapy is to be administered to the subject.

11. The use of claim 10, wherein the additional anti-cancer therapy is surgery, chemotherapy, radiation therapy, immunotherapy, biologic therapy, or a combination thereof.

12. The use of any one of claims 1 to 11, wherein the medicament further comprises a pharmaceutically acceptable excipient.

13. The use of any one of claims 1 to 12, wherein a histone deacetylase (HDAC) inhibitor is to be further administered to the subject.

14. The use of claim 13, wherein the HDAC inhibitor is vorinostat.

15. The use of any one of claims 1 to 14, wherein the subject is mammalian.


16. The use of claim 15, wherein the subject is human.

17. The use of any one of claims 1 to 16, wherein the medicament is to be administered in an amount sufficient to reduce viability of hedgehog pathway-dependent cancerous cells in the subject.

18. The use of any one of claims 1 to 17, wherein the medicament is to be administered in an amount sufficient to reduce production of Gli 1 mRNA in hedgehog pathway-dependent cancerous cells in the subject.

19. The use of any one of claims 1 to 18, wherein the medicament is to be administered in an amount sufficient to reduce growth and cell proliferation of hedgehog pathway-dependent cancerous cells in the subject.

20. Use of a compound of the formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting growth or proliferation of a hedgehog pathway-dependent cancerous cell.

21. The use according to claim 20, wherein the hedgehog pathway-dependent cancerous cell is a basal cell carcinoma (BCC) cell.

22. The use of claim 20 or 21, wherein the hedgehog pathway-dependent cancerous cell comprises a constitutively active hedgehog pathway.


~~23. The use of any one of claims 20 to 22, wherein the hedgehog pathway-dependent cancerous cell is *in vivo* or *in vitro*.~~

2423. The use of any one of claims 20 to 2322, wherein the hedgehog pathway-dependent cancerous cell is a human cancerous cell.

2524. The use of any one of claims 20 to 2423, further comprising contacting the hedgehog pathway-dependent cancerous cell with a deacetylase (HDAC) inhibitor.

2625. The use of claim 2524, wherein the HDAC inhibitor is vorinostat.

2726. A composition comprising a compound of the formula:



or a pharmaceutically acceptable salt thereof, for use in the treatment of a hedgehog pathway-dependent cancer.

2827. The composition of claim 2726, wherein the cancer is basal cell carcinoma (BCC).

2928. The composition of claim 27-26 or 2827, further comprising a histone deacetylase (HDAC) inhibitor.

3029. The composition of claim 2928, wherein the HDAC inhibitor is vorinostat.

30. An *in vitro* method of inhibiting growth or proliferation of a hedgehog pathway-dependent cancerous cell, the method comprising contacting the hedgehog pathway-dependent cancerous cell with an effective amount of CRT0422839 or CRT0364436, or a pharmaceutically acceptable salt thereof.

31. The *in vitro* method of claim 30, wherein the hedgehog pathway-dependent cancerous cell is a human cancerous cell.

32. The *in vitro* method of claim 30 or 31, further comprising contacting the hedgehog pathway-dependent cancerous cell with a deacetylase (HDAC) inhibitor.

33. The *in vitro* method of claim 32, wherein the HDAC inhibitor is vorinostat.